Skip to content

XOMA Corporation XOMA Current ratio

Current ratio at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
21.3×+16.0×
Royalty Pharma logo
Royalty PharmaRPRX
2.7×+1.1×
Theravance Biopharma logo
Theravance BiopharmaTBPH
13.1×+8.4×
Innoviva, Inc. logo
Innoviva, Inc.INVA
21.1×+18.7×
Zymeworks logo
ZymeworksZYME
10.8×+6.1×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-0.4×

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$745.16M+159%
Enterprise value$784.29M+151%
P/E22×
P/S15.4×+8.6×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×

Where this comes from

Calculated from XOMA Corporation’s reported figures.

Based on the most recent quarter.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's current ratio?
XOMA Corporation (XOMA) reported current ratio of 3.6× in Q1 2026.
How has XOMA Corporation's current ratio changed year-over-year?
XOMA Corporation's current ratio decreased by 35.2% year-over-year, from 5.5× to 3.6×.
What is the long-term trend for XOMA Corporation's current ratio?
Over 5 years (2020 to 2025), XOMA Corporation's current ratio has grown at a -14.0% compound annual growth rate (CAGR), from 7.2× to 3.4×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.